|
Inventions
|
J01.897.400 |
|
|
Facility Design and Construction
|
D005160 |
[Architecture, exterior and interior design, and construction of facilities other than hospitals, e.g., dental schools, medical schools, ambulatory care clinics, and specified units of health care facilities. The concept also includes architecture, design, and construction of specialized contained, controlled, or closed research environments including those of space labs and stations.
] |
|
Facility Regulation and Control
|
D005161 |
[Formal voluntary or governmental procedures and standards required of hospitals and health or other facilities to improve operating efficiency, and for the protection of the consumer.
] |
|
Thiazolidinediones
|
D02.886.675.933 |
|
|
Cystatin B
|
D12.776.215.200 |
|
|
Cystatins
|
D12.776.215 |
|
|
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
|
D019796 |
[A stable prostaglandin endoperoxide analog which serves as a thromboxane mimetic. Its actions include mimicking the hydro-osmotic effect of VASOPRESSIN and activation of TYPE C PHOSPHOLIPASES. (From J Pharmacol Exp Ther 1983;224(1): 108-117; Biochem J 1984;222(1):103-110)
] |
|
3-Iodobenzylguanidine
|
D019797 |
[A guanidine analog with specific affinity for tissues of the sympathetic nervous system and related tumors. The radiolabeled forms are used as antineoplastic agents and radioactive imaging agents. (Merck Index, 12th ed) MIBG serves as a neuron-blocking agent which has a strong affinity for, and retention in, the adrenal medulla and also inhibits ADP-ribosyltransferase.
] |
|
Genes, Intracisternal A-Particle
|
G05.360.340.358.024.875.360 |
|
|
Neopterin
|
D019798 |
[A pteridine derivative present in body fluids; elevated levels result from immune system activation, malignant disease, allograft rejection, and viral infections. (From Stedman, 26th ed) Neopterin also serves as a precursor in the biosynthesis of biopterin.
] |
|
Anaerobiospirillum
|
B03.660.250.018.750.050 |
|
|
Succinivibrionaceae
|
B03.660.250.018.750 |
|
|
Matrix Metalloproteinase 1
|
D020781 |
[A member of the metalloproteinase family of enzymes that is principally responsible for cleaving FIBRILLAR COLLAGEN. It can degrade interstitial collagens, types I, II and III.
] |
|
Uroporphyrinogen Decarboxylase
|
D08.811.520.224.125.900 |
|
|
Matrix Metalloproteinases
|
D020782 |
[A family of zinc-dependent metalloendopeptidases that is involved in the degradation of EXTRACELLULAR MATRIX components.
] |
|
Confidentiality
|
I01.880.604.473.650.500 |
|
|
Patient Rights
|
I01.880.604.473.650 |
|
|
Matrix Metalloproteinase 9
|
D020780 |
[An endopeptidase that is structurally similar to MATRIX METALLOPROTEINASE 2. It degrades GELATIN types I and V; COLLAGEN TYPE IV; and COLLAGEN TYPE V.
] |
|
Cathepsin C
|
D020789 |
[A papain-like cysteine protease that has specificity for amino terminal dipeptides. The enzyme plays a role in the activation of several pro-inflammatory serine proteases by removal of their aminoterminal inhibitory dipeptides. Genetic mutations that cause loss of cathepsin C activity in humans are associated with PAPILLON-LEFEVRE DISEASE.
] |
|
Central Nervous System Venous Angioma
|
D020787 |
[A vascular anomaly characterized by a radial or wedge-shaped arrangement of dilated VEINS draining into a larger vein in the brain, spinal cord, or the meninges. Veins in a venous angioma are surrounded by normal nervous tissue, unlike a CENTRAL NERVOUS SYSTEM CAVERNOUS HEMANGIOMA that lacks intervening nervous tissue. Drainage of venous angioma is fully integrated with the body's venous system, therefore, in most cases there is no clinical signs and rare bleeding.
] |
